Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bausch Health Companies Inc BHC


Primary Symbol: T.BHC

Healthcare
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with... see more

Recent & Breaking News (TSX:BHC)

Bausch Health Releases First Annual Corporate Social Responsibility Report

PR Newswire September 27, 2018

Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)

GlobeNewswire September 27, 2018

Bausch Health Announces Redemption Of $125 Million Aggregate Principal Amount Of Its Outstanding 7.50% Senior Notes Due 2021

PR Newswire September 26, 2018

Bausch Health Announces Participation In Upcoming Investor Conferences

PR Newswire September 24, 2018

Bausch Health Announces Resolution Of XIFAXAN® Intellectual Property Litigation

PR Newswire September 12, 2018

Bausch Health Reduces Debt By Additional $107 Million, Eliminating All Remaining Mandatory Amortization For 2018

PR Newswire September 11, 2018

Salix Announces U.S. Launch of PLENVU®, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies

PR Newswire September 11, 2018

LUMIFY™ Redness Reliever Eye Drops Honored By The National Association of Chain Drug Stores As Product Showcase Winner

PR Newswire September 10, 2018

Bausch Health Companies To Participate At The Morgan Stanley Global Healthcare Conference

PR Newswire September 6, 2018

Bausch + Lomb Announces Publication Of Pivotal Phase 3 Data On Loteprednol Etabonate Ophthalmic Gel, 0.38% In Journal Of Cataract And Refractive Surgery

PR Newswire September 5, 2018

US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine) At 2018 PAINWeek Conference

PR Newswire September 4, 2018

FDA Accepts Resubmission Of New Drug Application For Duobrii™1 (Halobetasol Propionate And Tazarotene) Lotion

PR Newswire August 29, 2018

Ortho Dermatologics Receives FDA Approval For ALTRENO™ (tretinoin 0.05%) Lotion For Acne

PR Newswire August 24, 2018

RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation

GlobeNewswire August 20, 2018

Ortho Dermatologics Resubmits U.S. New Drug Application For DUOBRII™ (halobetasol propionate and tazarotene) Lotion

PR Newswire August 15, 2018

Ortho Dermatologics Announces 2018 Aspire Higher Scholarship Recipients

PR Newswire August 8, 2018

Bausch Health Companies Inc. Announces Second-Quarter 2018 Results

PR Newswire August 7, 2018

US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA™ (lofexidine) 0.18 Mg Tablets

PR Newswire August 6, 2018

Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center

PR Newswire August 3, 2018

Bausch Health Companies Inc. Completes Name Change

PR Newswire July 13, 2018